| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 83.4 | 94.7 |
| Gross profit | 59.1 | 77.9 |
| Profit before tax | 7.0 | 18.8 |
| Net income | 5.6 | 8.9 |
| EPS (diluted, $ a share) | $0.11 | $0.18 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Net income, year on year | -37.2% |
|---|---|
| Revenue, year on year | -12.0% |
| Gross margin | 70.9% |
| Operating margin | 6.5% |
10-Q filed with the SEC, NASDAQ: STAA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Staar Surgical Co: key numbers
- Share price
- $26.01Close, Nov 16
- Market cap
- $1.31B
- Shares outstanding
- 50.2MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Ophthalmic GoodsSIC 3851
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Staar Surgical Co
All →Staar Surgical Earnings Call: Key Takeaways
STAAR Surgical delivered record nine-month revenue driven by a structural shift from lasers to lenses, though supply constraints in China and temporary margin pressures from ERP implementation impacted the quarter.
- Call
- Nov 4, 2026, 5:30 PM ET
Staar Surgical Financial Results
STAAR Surgical reported third quarter 2026 net sales of $83.4 million and net income of $5.6 million. The company achieved record year-to-date revenue of $270.5 million and authorized a new $50 million share repurchase program during the period.
- Term
- Q3 2026
Staar Surgical Executive Compensation
STAAR Surgical Company appointed former CEO David Bailey as Chief Commercial Officer, effective September 8, 2026. His compensation package includes an annual base salary of approximately $575,000, a target cash bonus of 60% of base salary, and initial equity grants totaling $2.25 million in value (comprised of an $850,000 sign-on grant and a $1.4 million annual long-term incentive award).
- Counterparty
- David Bailey